NYSE · GKOS
Glaukos Corporation
$242.48+$61.05 (+33.65%)
Glaukos Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.51% below the high.
Loading market information…
NASDAQ · OCUL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ocular Therapeutix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ocular Therapeutix, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.36. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ocular Therapeutix, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 5, 2025 | -$0.37-27.59% vs estimate | $10.63M-18.8% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | -$0.29-20.83% vs estimate | $17.08M-0.17% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.26-13.04% vs estimate | $15.43M-8.68% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
19 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $25.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$242.48+$61.05 (+33.65%)
Glaukos Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.51% below the high.
$20.40$0.00 (0.0%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.49% below the high.
$100.40+$3.36 (+3.46%)
Kodiak Sciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.46% below the high.
$25.24+$0.63 (+2.56%)
STAAR Surgical Company’s quoted price sits in the lower half of its reported 52-week range, 29.63% below the high.
$29.99+$0.60 (+2.04%)
Harrow Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.32% below the high.
$32.51-$0.35 (-1.07%)
SpyGlass Pharma, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$8.24+$0.26 (+3.26%)
Oculis Holding AG’s quoted price sits in the lower half of its reported 52-week range, 76.1% below the high.
$0.74-$0.03 (-4.15%)
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
